Browse online courses and resources available for Continuing Medical Education Credit.

CME Courses
Collapse Advanced Lung Cancers: What

Access Course

 

884791.jpg?interpolation=lanczos-none&resize=300:225Experts review the latest abstracts and developments in NSCLC, SCLC, mesothelioma, and brain metastases. 
 

This activity is intended for hematologists/oncologists and pulmonologists.
 

The goal of this activity is to improve knowledge and implementation of clinically relevant data in the area of lung cancer from recent conferences.

 

 

 

Approximate Time to Complete: 30 minutes

 

Credit Available: Nov. 20, 2017 - Nov. 20, 2018

 

Developed through a partnership between SITC and Medscape.

sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
Original Course Date: November 20, 2017

Approved Credit:
  • ACCME: 0.50 hours AMA PRA Category 1 Credit(s)™
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits

  • MORE INFOMORE INFO Advanced Lung Cancers: What
    Collapse Best Practices in the Management of SCCHN

    Access Course

     

    884784.jpg?interpolation=lanczos-none&resize=300:225Dr. Charu Aggarwal reviews the use of immunotherapy in metastatic SCCHN in two case studies.

    This activity is intended for oncologists, surgeons, pathologists, nurses, and pharmacists.
     

    The goal of this activity is to review the latest data and use of immune checkpoint blockade in patients with relapsed or metastatic squamous cell cancer of the head and neck (SCCHN).

     

     

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Dec. 12, 2017 - Dec. 12, 2018

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 12, 2017

    Approved Credit:
  • ACCME: 1 hour AMA PRA Category 1 Credit(s)™
  • ABIM: 1 hour ABIM MOC Part 2 Credits
  • ANCC: 1 hour Contact Hour
  • ACPE: 1 hour CEU

  • MORE INFOMORE INFO Best Practices in the Management of SCCHN
    Collapse Case Studies in Advanced NSCLC: What Would You Do?

    Access Course

     

    882821.jpg?interpolation=lanczos-none&resize=300:225

    Enhance your clinical skills as you engage with patients in an objective and realistic interactive simulation. Treat patients, diagnose medical conditions, and prescribe medications. There are no limits to your choices—order from thousands of labs, diagnoses, devices, and drugs using an intuitive patient chart-based interface.

     

    Powerful metrics track your performance and provide instant expert feedback on your decisions. Upon completion, results will be presented, along with author commentary on each case.

     

     

    This activity is intended for hematology/oncology specialists, pulmonologists, and pathologists.

    The goal of this activity is to build healthcare professionals’ confidence in strategies for the individualized treatment of the patient with non-small cell lung cancer (NSCLC) and to ensure that best practices are applied across a variety of clinical presentations

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Dec. 06, 2017 - Dec. 06, 2018

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 06, 2017

    Approved Credit:
  • ACCME: 1.25 hours AMA PRA Category 1 Credit(s)™
  • ABIM: 1.25 hours ABIM MOC Part 2 Credits

  • MORE INFOMORE INFO Case Studies in Advanced NSCLC: What Would You Do?
    Collapse Challenges and Opportunities in the Management of Advanced Gastric Cancer

    Access Course

     

    884785.jpg?interpolation=lanczos-none&resize=300:225

    Dr Ajani examines the emerging use of immunotherapy in the management of advanced gastric cancer via 2 patient cases.
     

    This activity is intended for oncologists, gastroenterologists, and surgeons.
     

    The goal of this activity is to discuss the latest advances in the use of immunotherapy in patients with advanced gastric cancer.

     

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Dec. 14, 2017 - Dec. 14, 2018

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 14, 2017

    Approved Credit:
  • ACCME: 1 hour AMA PRA Category 1 Credit(s)™
  • ABIM: 1 hour ABIM MOC Part 2 Credits

  • MORE INFOMORE INFO Challenges and Opportunities in the Management of Advanced Gastric Cancer
    Collapse Challenging Case Studies in Advanced HCC: What Would You Do?

    Access Course

     

    881521.jpg?interpolation=lanczos-none&resize=300:225

    Enhance your clinical skills as you engage with patients in an objective and realistic interactive simulation. Treat patients, diagnose medical conditions, and prescribe medications. There are no limits to your choices - order from thousands of labs, diagnoses, devices and drugs using an intuitive patient chart-based interface.

     

    Powerful metrics track your performance and provide instant expert feedback on your decisions. Upon completion, results will be presented, along with author commentary on each case.

     

    This activity is intended for hematology/oncology specialists, gastroenterologists, and pathologists.

    The goal of this activity is to build healthcare professionals’ confidence in strategies for the individualized treatment of patients with hepatocellular carcinoma (HCC) and to ensure that best practices are applied across a variety of clinical presentations.

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Nov. 27, 2017 - Nov. 27, 2018

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 27, 2017

    Approved Credit:
  • ACCME: 1.50 hours AMA PRA Category 1 Credit(s)™
  • ABIM: 1.50 hours ABIM MOC Part 2 Credits

  • MORE INFOMORE INFO Challenging Case Studies in Advanced HCC: What Would You Do?
    Collapse Checkpoint Inhibitors: Managing Immune-Mediated Side Effects

    Access Course

     

    890963.jpg?interpolation=lanczos-none&resize=300:*Follow the cases of 2 patients who developed immune-related adverse events following treatment with immune checkpoint blockade.

     

    This activity is intended for oncologists, emergency medicine physicians, pulmonologists, and nurses.

     

    The goal of this activity is to review strategies for identifying and managing adverse events associated with treatment with immune checkpoint blockade.

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Feb. 28, 2018 - Feb. 28, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: February 28, 2018

    Approved Credit:
  • ACCME: 0.50 hours AMA PRA Category 1 Credit(s)™
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ANCC: 0.50 hours Contact Hour

  • MORE INFOMORE INFO Checkpoint Inhibitors: Managing Immune-Mediated Side Effects
    Collapse Emerging Considerations in Immune Checkpoint Inhibitors: Esophago-Gastric Cancer

    Access Course

     

    884766.jpg?interpolation=lanczos-none&resize=300:225

    This activity is intended for oncologists, gastroenterologists, and surgeons.

     

    The goal of this activity is to discuss the evolving role of cancer immunotherapy in gastric and gastroesophageal junction cancer.

     

     

     

     

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Nov. 29, 2017 - Nov. 29, 2018

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 29, 2017

    Approved Credit:
  • ACCME: 0.50 hours AMA PRA Category 1 Credit(s)™
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ANCC: 0.50 hours Contact Hour

  • MORE INFOMORE INFO Emerging Considerations in Immune Checkpoint Inhibitors: Esophago-Gastric Cancer
    Collapse Emerging Considerations in the Use of Immune Checkpoint Inhibitors: HCC

    Access Course

     

    892102.jpg?interpolation=lanczos-none&resize=300:*Drs Greten and El-Khoueiry discuss the emergence of checkpoint inhibition therapy in the treatment of advanced HCC.

     

    This activity is intended for oncologists, gastroenterologists, surgeons, and nurses.
     

    The goal of this activity is to review the latest data on the efficacy and safety of immune checkpoint inhibitors in the management of patients with advanced hepatocellular carcinoma (HCC).

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Mar. 09, 2018 - Mar. 09, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: March 09, 2018

    Approved Credit:
  • ACCME: 0.50 hours AMA PRA Category 1 Credit(s)™
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ANCC: 0.50 hours Contact Hour

  • MORE INFOMORE INFO Emerging Considerations in the Use of Immune Checkpoint Inhibitors: HCC
    Collapse Emerging Considerations in the Use of Immune Checkpoint Inhibitors: What is MSI?

    Access Course

     

    880309.jpg?interpolation=lanczos-none&resize=300:225Drs Overman and Sinicrope discuss the emergence of MSI-H: what it is, how it may be used to help guide treatment with immunotherapy.


    The goal of this activity is to discuss the evolving role of MSI to help guide cancer immunotherapies.

     

    This activity is intended for oncologists, gastroenterologists, and pathologists

     

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Nov. 28, 2017 - Nov. 28, 2018

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 28, 2017

    Approved Credit:
  • ACCME: 0.50 hours AMA PRA Category 1 Credit(s)™
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ANCC: 0.50 hours Contact Hour

  • MORE INFOMORE INFO Emerging Considerations in the Use of Immune Checkpoint Inhibitors: What is MSI?
    Collapse Expanding the Treatment Possibilities in SCCHN: What Role Do Cancer Immunotherapies Have?

    Access Course

     

    884823.jpg?interpolation=lanczos-none&resize=300:225Drs Haddad, Bauman, and Mehra discuss the latest data as well as practicalities of using immunotherapy in SCCHN.


    This activity is intended for oncologists, surgeons, and pathologists.
     

    The goal of this activity is to discuss the recent advances in the use of immunotherapy for head and neck cancer.

     

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Nov. 29, 2017 - Nov. 29, 2018

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 29, 2017

    Approved Credit:
  • ACCME: 0.50 hours AMA PRA Category 1 Credit(s)™
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits

  • MORE INFOMORE INFO Expanding the Treatment Possibilities in SCCHN: What Role Do Cancer Immunotherapies Have?
    Collapse Immune Checkpoint Inhibitors in Lung Cancer: No Longer The Road Less Traveled?

    Access Course

     

    Immune Checkpoint Inhibitors in Lung Cancer: No Longer the Road Less Traveled?Experts discuss emerging clinical trial data on the use of immune checkpoint inhibitors in the management of advanced lung cancers.

     

    This activity is intended for  oncologists, pulmonologists, and pathologists.

     

    The goal of this activity is to discuss how to integrate emerging clinical trial data on the use of immune checkpoint inhibitors into the management of patients with advanced lung cancers.

     

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Nov. 9, 2018- Nov. 9, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 09, 2018

    Approved Credit:
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™

  • MORE INFOMORE INFO Immune Checkpoint Inhibitors in Lung Cancer: No Longer The Road Less Traveled?
    Collapse Introduction to Immunology – <i>Second Edition</i>

    Actively engage in the second edition of this interactive course about the immune system. The course provides an overview of the immune system, focusing on the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. This foundational knowledge presented in this course is critical to understanding how the immune system can be harnessed to treat cancer through immunotherapy. 

    intro_to_immunology_second_edition_screenshot_2.png

    Credit Available: September 28, 2018- September 29, 2018

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. (as of Aug. 21, 2018). 

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.

    Educational Objectives
    After completing this activity, the participant should be better able to:

    • Describe the function of the components of the immune system, including relevant cells, molecules and organs of the immune system.
    • Differentiate between the adaptive immune system and the innate immune system.
    • Recognize the barriers to effective immunotherapy, including mechanisms by which tumors locally disable and/or evade the immune system. 

     

    Faculty
    Christian M. Capitini, MD
    Assistant Professor
    University of Wisconsin Carbone Cancer Center
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-18-400-H01-P)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.  Designated for 0.5 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Christian Capitini, MD: Consulting Fees at Nektar Therapeutics

    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period September 28, 2018 through September 28, 2019 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please following the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Introduction to Immunology – Second Edition.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Complete the post-test and survey.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service.

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

    Original Course Date: September 28, 2018

    Approved Credit:
  • ACPE: 1 hour CEU
  • ANCC: 1 hour Contact Hour
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 1 hour AMA PRA Category 1 Credit(s)™

  • MORE INFOMORE INFO Introduction to Immunology – <i>Second Edition</i>
    Collapse Management of Head & Neck Cancer at Disease Progression: Now What?

    Access Course

     

    886437.jpg?interpolation=lanczos-none&resize=300:225Learn to select appropriate therapies while managing treatment side effects to improve outcomes for patients with progression of head and neck cancers.


    This activity is intended for hematology/oncology specialists, surgeons, and pathologists.
     

    The goal of this activity is to build healthcare professionals’ confidence in strategies for the individualized treatment of the patient with squamous cell carcinoma of the head and neck (SCCHN) that has progressed despite treatment, and to ensure that best practices are applied across a variety of clinical presentations.

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Dec. 20, 2017 - Dec. 20, 2018

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 20, 2017

    Approved Credit:
  • ACCME: 1.75 hours AMA PRA Category 1 Credit(s)™
  • ABIM: 1.75 hours ABIM MOC Part 2 Credits

  • MORE INFOMORE INFO Management of Head & Neck Cancer at Disease Progression: Now What?
    Collapse Metastatic Melanoma: Optimizing Management in the Continuum of Care

    Access Course

     

    884844.jpg?interpolation=lanczos-none&resize=300:225Dr Ahmad Tarhini explores some of the challenges of treating patients with metastatic melanoma through the use of 2 cases.

     

    This activity is intended for oncologists, dermatologists, pathologists, nurses, and other healthcare professionals who treat patients with melanoma.
     

    The goal of this activity is to explore the use of immunotherapy in patients with metastatic melanoma.

     

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Dec. 17, 2017 - Dec. 17, 2018

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 17, 2017

    Approved Credit:
  • ACCME: 0.50 hours AMA PRA Category 1 Credit(s)™
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ANCC: 0.50 hours Contact Hour

  • MORE INFOMORE INFO Metastatic Melanoma: Optimizing Management in the Continuum of Care
    Collapse Metastatic Melanoma: What Would You Do?

    Access Course

     

    883120.jpg?interpolation=lanczos-none&resize=300:225

    Enhance your clinical skills as you engage with patients in an objective and realistic interactive simulation. Treat patients, diagnose medical conditions, and prescribe medications. There are no limits to your choices - order from thousands of labs, diagnoses, devices and drugs using an intuitive patient chart-based interface.
     

    Powerful metrics track your performance and provide instant expert feedback on your decisions. Upon completion, results will be presented, along with author commentary on each case.

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Nov. 21, 2017 - Nov. 21, 2018

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 21, 2017

    Approved Credit:
  • ACCME: 1.50 hours AMA PRA Category 1 Credit(s)™
  • ABIM: 1.50 hours ABIM MOC Part 2 Credits

  • MORE INFOMORE INFO Metastatic Melanoma: What Would You Do?
    Collapse Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

    Access Course

     

    884775.jpg?interpolation=lanczos-none&resize=300:225An oncologist, a pulmonologist, and a pathologist discuss multidisciplinary management of advanced NSCLC. 


    The goal of this activity is to improve knowledge of multidisciplinary care with regard to the use of immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC).


    This activity is intended for hematology/oncology specialists, pulmonologists, and pathologists.

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Dec. 19, 2017 - Dec. 19, 2018

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 19, 2017

    Approved Credit:
  • ACCME: 0.50 hours AMA PRA Category 1 Credit(s)™
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits

  • MORE INFOMORE INFO Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC
    Collapse Novel Concepts in the Management of RCC

    Access Course

     

    900287.jpg?interpolation=lanczos-none&resize=300:*Drs Rini and McDermott discuss the latest approvals and ongoing research into immunotherapy for advanced RCC.
     

    This activity is intended for oncologists, urologists, and other healthcare professionals who treat patients with RCC.

     

    The goal of this activity is to discuss the evolving role of cancer immunotherapy in renal cell carcinoma (RCC).

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Sep. 19, 2018- Sep. 19, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: September 19, 2018
    MORE INFOMORE INFO Novel Concepts in the Management of RCC
    Collapse Optimizing Outcomes in Bladder Cancer: Case Studies

    Access Course

     

    884786.jpg?interpolation=lanczos-none&resize=300:225Dr Petros Grivas explores the role of immunotherapy in advanced bladder cancer through a platinum-eligible and a platinum-ineligible patient.


    This activity is intended for oncologists, urologists, surgeons, pharmacists, and other healthcare professionals who treat patients with bladder cancer.


    The goal of this activity is to discuss the latest advances in the use of immunotherapy in patients with advanced bladder cancer.

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Dec. 20, 2017-Dec. 20, 2018

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 20, 2017

    Approved Credit:
  • ACCME: 1 hour AMA PRA Category 1 Credit(s)™
  • ACPE: 1 hour CEU
  • ABIM: 1 hour ABIM MOC Part 2 Credits

  • MORE INFOMORE INFO Optimizing Outcomes in Bladder Cancer: Case Studies
    Collapse Optimizing Outcomes: Multidisciplinary Management of Advanced Bladder Cancer

    Access Course

     

    902370.jpg?interpolation=lanczos-none&resize=300:*Drs Milowsky and Smith discuss the evolving use of checkpoint inhibition in patients with advanced bladder cancer.

     

    This activity is intended for oncologists, urologists, nurses, and other healthcare professionals who treat patients with bladder cancer.

     

    The goal of this activity is to discuss the most up-to-date use of immunotherapy in the treatment of patients with advanced bladder cancer.

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Sep. 27, 2018- Sep. 27, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: September 27, 2018

    Approved Credit:
  • ANCC: 0.50 hours Contact Hour
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™

  • MORE INFOMORE INFO Optimizing Outcomes: Multidisciplinary Management of Advanced Bladder Cancer
    Collapse Renal Cell Carcinoma (RCC) Upon Disease Progression: Next Steps

    Access Course

     

    885328.jpg?interpolation=lanczos-none&resize=300:225Enhance your clinical skills as you engage with patients in an objective and realistic interactive simulation. Treat patients, diagnose medical conditions, and prescribe medications. There are no limits to your choices—order from thousands of labs, diagnoses, devices, and drugs using an intuitive patient chart-based interface.

     

    Powerful metrics track your performance and provide instant expert feedback on your decisions. Upon completion, results will be presented, along with author commentary on each case.

     

     

    This activity is intended for hematology/oncology specialists, pulmonologists, and pathologists.

     

    The goal of this activity is to build healthcare professionals’ confidence in strategies for the individualized treatment of the patient with renal cell carcinoma (RCC) and to ensure that best practices are applied across a variety of clinical presentations.

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Dec. 15, 2017 - Dec. 15, 2018

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 15, 2017

    Approved Credit:
  • ACCME: 1 hour AMA PRA Category 1 Credit(s)™
  • ABIM: 1 hour ABIM MOC Part 2 Credits

  • MORE INFOMORE INFO Renal Cell Carcinoma (RCC) Upon Disease Progression: Next Steps
    Collapse The Emerging Role of Immunotherapy in Hodgkin Lymphoma

    Access Course

     

    884773.jpg?interpolation=lanczos-none&resize=300:225

    Drs Ansell, Armand, and Diefenbach discuss the latest research into the use of checkpoint inhibition in Hodgkin lymphoma.

     

    This activity is intended for hematologists, pathologists, and other healthcare professionals who treat patients with Hodgkin lymphoma.The goal of this activity is to discuss the recent advances in the use of immunotherapy for Hodgkin lymphoma.

     

     

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Nov. 14, 2017 - Nov. 14, 2018

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 14, 2017

    Approved Credit:
  • ACCME: 0.50 hours AMA PRA Category 1 Credit(s)™
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ANCC: 0.50 hours Contact Hour

  • MORE INFOMORE INFO The Emerging Role of Immunotherapy in Hodgkin Lymphoma
    Collapse The Evolving Role of Immunotherapy in NSCLC: Pearls for Clinical Practice

    Access Course

     

    890347.jpg?interpolation=lanczos-none&resize=300:*Faculty discuss recent and ongoing clinical trials that affect clinical decisions with the use of immunotherapy in NSCLC.


    This activity is intended for hematology/oncology specialists and pharmacists.
     

    The goal of this activity is to improve knowledge of clinical trial designs and practical application of data in order to improve management of patients with non-small cell lung cancer (NSCLC).

     

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Feb. 27, 2018 - Feb. 27, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: February 27, 2018

    Approved Credit:
  • ACCME: 0.50 hours AMA PRA Category 1 Credit(s)™
  • ACPE: 0.50 hours CEU
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits

  • MORE INFOMORE INFO The Evolving Role of Immunotherapy in NSCLC: Pearls for Clinical Practice
    Collapse The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer

    Access Course

     

    902337.jpg?interpolation=lanczos-none&resize=300:*Learn about current and emerging immunotherapy options and how to monitor for and manage immune-related adverse events.


    This activity is intended for nurses and nurse practitioners.

     

    The goal of this activity is to provide perspective on where immune checkpoint inhibitors fit into treatment paradigms, as well as on monitoring and management strategies for immune-related adverse events (irAEs).

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Sep. 26, 2018- Sep. 26, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: September 26, 2018

    Approved Credit:
  • ANCC: 0.50 hours Contact Hour
  • ABIM: 1 hour CEU

  • MORE INFOMORE INFO The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer
    Collapse Treatment Algorithms in Melanoma: Past, Present, and Future

    Access Course

     

    882627.jpg?interpolation=lanczos-none&resize=300:225Watch these experts discuss updates in the use of immunotherapy in melanoma, including novel approaches and immunotherapy in the adjuvant setting.

     

    This activity is intended for oncologists, dermatologists, and pathologists.

     

    The goal of this activity is to discuss both the practicalities of using checkpoint inhibitors in melanoma and the emergence of new immunotherapeutic strategies.

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Nov. 13, 2017 - Nov. 13, 2018

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 14, 2017

    Approved Credit:
  • ACCME: 0.50 hours AMA PRA Category 1 Credit(s)™
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits

  • MORE INFOMORE INFO Treatment Algorithms in Melanoma: Past, Present, and Future